Agios Pharmaceuticals

ISIN US00847X1046

WKN A1W2RM

Marktkapitalisatie (in EUR)

1.408 m

Land

Verenigde Staten

Sector

Gezondheidszorg

Dividendrendement

0,00%

Overzicht

Koers

Beschrijving

Agios Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf dat zich bezighoudt met onderzoek, meerdere romans en onderzoekstherapieën in preklinische ontwikkeling. Het richt zich op celmetabolisme en klassieke hematologie. Het bedrijf werd op 7 augustus 2007 opgericht door Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson en Shin-Shan Michael Su en heeft zijn hoofdkantoor in Cambridge, MA.

Toon meer Toon minder

Gezondheidszorg Biofarmaceutica Systeemspecifieke Biofarmaceutica Verenigde Staten

Grafiek

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR	1.408 m
WPA, EUR	-6,30
KBV	1,3
K/W	3,8
Dividendrendement	0,00%

Winst- en verliesrekening (2024)

Omzet, EUR	34 m
Netto-inkomen, EUR	623 m
Winstmarge	1.845,92%

In welke ETF zit Agios Pharmaceuticals?

Er zijn 4 ETF's die Agios Pharmaceuticals bevatten. Al deze ETF's staan in de tabel hieronder. De ETF met de grootste weging van Agios Pharmaceuticals is de iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).

ETF	Weging	Investeringsfocus	Fondsgrootte (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	0,21%	Aandelen Verenigde Staten Gezondheidszorg Biotech	45
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing	0,00%	Aandelen Wereld Sociaal/Milieu	497
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing	0,00%	Aandelen Noord-Amerika Sociaal/Milieu	27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist)	0,04%	Aandelen Verenigde Staten Small Cap	185

Prestaties

Rendementsoverzicht

YTD	+5,63%
1 maand	+5,63%
3 maanden	-33,51%
6 maanden	-26,73%
1 jaar	-30,29%
3 jaar	-10,95%
5 jaar	-34,60%
Since inception	-45,36%
2025	-27,36%
2024	+53,62%
2023	-19,14%
2022	-13,92%

Maandelijks rendement in een heat map

Risico

Risk metrics in this section:

Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.

ETF-rendementen zijn inclusief dividenduitkeringen (indien van toepassing).